Important Information for Health Care Providers

This patient is being treated with **Tecentriq (atezolizumab),** which can cause immune-related adverse reactions that involve the lungs, liver, intestines, hormone glands, and other organs, as well as infusion-related reactions. Early diagnosis and appropriate management are essential to minimize any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other cause. Based on the severity of the adverse reaction, withhold Tecentriq and administer corticosteroids.

Specific guidelines for managing immune-related adverse reactions are provided in the **Summary of Product Characteristics** for atezolizumab and Physician Education Materials available at www.ema.europa.eu. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.

Restart Tecentriq if the adverse reaction remains at Grade 1 or less within 12 weeks after onset of adverse reaction and corticosteroid dose is ≤ 10 mg prednisone or equivalent per day.

Please contact the patient's clinic/contact nurse for more information.

Assess patients for signs and symptoms of pneumonitis, hepatitis, colitis, endocrinopathies (including hypophysitis, adrenal insufficiency, type 1 diabetes mellitus, hypothyroidism, hyperthyroidism), myocarditis, pancreatitis, nephritis and infusion related reactions. Other immune-related adverse reactions reported in patients receiving atezolizumab include: neuropathies (Guillain-Barré syndrome, myasthenic syndrome / Myasthenia Gravis), and meningoencephalitis.

Please consult the Summary of Product Characteristics for Tecentriq at fass.se

Select important safety information

Serious side effects may include pneumonitis, liver problems (hepatitis), intestinal problems (colitis), problems in hormone glands (for example thyroid problems or diabetes), nervous system, and other organs. These events may result in signs or symptoms such as:

Lungs: new or worsening cough, shortness of breath, chest pain.

Liver: yellowing of skin or the whites of eyes, severe nausea or vomiting, bleeding or bruising, dark urine, stomach pain.

Intestines: diarrhea (watery, loose or soft stools), blood in stools, stomach pain.

Hormone glands: extreme tiredness, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, feeling more hungry or thirsty than usual, need to urinate more often, increased sensitivity to cold or heat.

Brain: neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion, sleepiness.

Nerves: severe muscle weakness and numbness, tingling in your hands and feet.

Heart: chest pain, shortness of breath, irregular heart beat, decreased exercise tolerance, ankle swelling.

Pancreas: abdominal pain, nausea, vomiting.

Kidneys: changes in urine output and colour, pain in pelvis, and swelling of the body.

Reactions associated with infusion (during or within 1 day of infusion): fever, chills, shortness of breath, flushing.

Getting medical treatment immediately may stop the problems from becoming serious. Your doctor may decide to give you other medicines to prevent complications and reduce your symptoms, and may withhold the next dose or stop your treatment.

Roche AB,
Arvid Tydéns Allé, Box 1228, SE-171 23 Solna.
+46 8 726 12 00, www.roche.se

SE/TCN/1218/0001(1)a

Roche

PATIENT ALERT CARD TECENTRIQ®▼

TECENTRIQ®
atezolizumab

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you might get. If you experience side effects, talk to your doctor or nurse. You can also report side effects directly to Läkemedelsverket, www.lakemedelsverket.se

Important Reminders for Patients

TECENTRIQ® (atezolizumab) is a so called PD-L1 inhibitor, a type of immunotherapeutic medicine to treat adults with *advanced (metastatic) urothelial carcinoma and non small cell lung cancer.* Tecentriq is administered intravenously. Like all medicines, this medicine may cause side-effects, although not everybody gets them. It is important to tell your doctor **immediately** if you develop any of the signs or symptoms listed on this card after starting treatment with atezolizumab. Before you start atezolizumab or during your treatment, you should also tell your doctor immediately if you:

- Have an autoimmune disease (a condition where the body attacks its own cells, examples include autoimmune thyroid disease, systemic lupus erythematosus (SLE), Sjogren's syndrome, multiple sclerosis, rheumatoid arthritis, vasculitis, glomerulonephritis)
- Have been told that your cancer has spread to your brain
- Have any history of inflammation of your lungs (pneumonitis)
- Have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV)
- Have human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
- Have experienced serious side effects because of other antibody therapies that help your immune system to fight cancer
- Have been given medicines to stimulate your immune system such as inteferons or interleukin-2 as these medicines may worsen the side effects of atezolizumab
- Have been given medicines to suppress your immune system such as corticosteroids, since these medicines may interfere with the effect of atezolizumab
- Have been given a live, attenuated vaccine such as influenza intranasal vaccine, yellow fever vaccine

You should not start any other medicines during your treatment without talking to your doctor first.

If you develop any signs or symptoms listed on this card or if you notice any signs or symptoms not listed on this card, please contact your doctor immediately. Getting medical treatment early may stop the problem from becoming more serious.

If you have any further questions about your treatment or on the use of this medicine, please contact your doctor.

It is important that you carry this card with you at all times whilst you are receiving treatment with this medicine and to keep it with you until at least 5 months after your last dose of treatment. Please ensure you show this card to all Healthcare Professionals (including pharmacists and dentists), to any doctor involved in your treatment, and at any visits to the hospital.

Important

- **TECENTRIQ (atezolizumab)** can cause serious side effects that need to be treated right away.
- Symptoms may occur at any time during treatment or even after your treatment has ended.
- Call your doctor right away if you develop any of these new signs or symptoms listed on this card or if your symptoms should get worse.
- Also tell your doctor if you experience any other symptoms not listed on this card.
- Do not try to treat your symptoms on your own.
- Carry this card with you at all times, especially when you travel, whenever you go to an emergency department, or when you see another doctor.

Name of clinic

Contact nurse

Phone number

Phone number outside office hours

My name

My phone number

Emergency contact, and number